An interventional study of online CBCT-guided adaptive radiation therapy using a new software in Prostate Cancer, Cervical Cancer and Bladder Cancer, sponsored by The Netherlands Cancer Institute. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-01.
Sponsored by The Netherlands Cancer Institute · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Prostatic Neoplasms by The Netherlands Cancer Institute — 6 open to participants now, 7 under way, none of them phase 3. Prostatic Neoplasms · The Netherlands Cancer Institute.
Among the 16 studies in Prostatic Neoplasms by The Netherlands Cancer Institute, this one is the 4th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2023, is one of 8 with no phase, and was the 12th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →6 of the 16 studies in Prostatic Neoplasms by The Netherlands Cancer Institute are open now, in 1 country. Recruiting first, the newest first:
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+ · Men only
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+ · Men only
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+ · Men only
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+ · Men only
The Netherlands Cancer Institute
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 54 across the 13 interventional studies, 26 across the 3 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
The Netherlands Cancer Institute is the lead sponsor of 231 studies on the registry; 66 are open to participants now.
1 of the studies in Prostatic Neoplasms by The Netherlands Cancer Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07391982The Netherlands Cancer InstituteDose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two Fractions | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Prostatic Neoplasms by The Netherlands Cancer Institute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The accuracy of radiotherapy can be increased by correcting for geometric uncertainties and changes between radiotherapy fractions. These corrections are currently done with online adaptive treatment on a specialized linear accelerator (linac) for a small subset of patients. However, patients currently treated on a standard linac could also benefit from online adaptive radiotherapy. The objective is to determine the feasibility of online CBCT-guided adaptive radiation therapy on a standard Elekta linac.
General Inclusion Criteria:
Specific inclusion criteria for prostate cohort:
Specific inclusion criteria for cervical cohort:
Specific inclusion criteria for bladder cohort:
Specific inclusion criteria for lung cohort:
Specific inclusion criteria for head and neck cohort:
General Exclusion Criteria:
Specific for prostate cohort:
Specific for cervical cohort:
- Patients with a medical condition that severely compromises CBCT image quality (mainly hip prostheses).
Specific for bladder cohort:
Specific for lung cohort:
- Severe pulmonary complaints that could make the longer treatment time problematic (according to judgement of treating physician).
Specific for head and neck cohort:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The CBCT will be matched (translated and rotated) to the original planning CT with the clinical image registration software. A new software (the rotation simulator) reads both the match of the bony anatomy and the match of the prostate. This software also imports the original planning CT and structures and deforms the original planning CT to match the rotations and translations of pelvis and prostate, as seen in the CBCT. Both these new radiotherapy planning structures and the deformed planning CT are exported to the radiotherapy planning software (Monaco) and used to calculate the adaptive plan. This newly calculated plan will be exported to Mosaiq to treat the patient.
Device: online CBCT-guided adaptive radiation therapy using a new software
The CBCT will be matched (translated and rotated) to the original planning CT with the clinical image registration software. With in-house software, the target areas and the OARs will be deformed to or segmented on the anatomy of the CBCT. These adjusted radiotherapy structures are then send to the radiotherapy planning software (Monaco). There, the structures are visually inspected and, if needed, manually adjusted. Afterwards, Monaco calculates a new, online adaptive radiotherapy plan. After checking, the plan is exported to Mosaiq to treat the patient.
Device: online CBCT-guided adaptive radiation therapy using a new software
The CBCT will be matched (translated and rotated) to the original planning CT with the clinical image registration software. With in-house software, the target areas and the OARs will be deformed or segmented to the anatomy of the CBCT. These adjusted radiotherapy structures are then send to the radiotherapy planning software (Monaco). There, the structures are visually inspected and, if needed, manually adjusted. Afterwards, Monaco calculates a new, online adaptive radiotherapy plan. After checking, the plan is exported to Mosaiq to treat the patient.
Device: online CBCT-guided adaptive radiation therapy using a new software
The CBCT will be matched (translated and rotated) to the original planning CT with the clinical image registration software. The rotation simulator reads both the registration of the primary tumor and of the lymph nodes (via the carina). This software also imports the original planning CT and structures and deforms the original planning CT to match the rotations and translations of the primary tumor and lymph nodes, as seen in the CBCT. Both these new radiotherapy planning structures and the deformed planning CT are exported to the radiotherapy planning software (Monaco) and used to calculate the adaptive plan. This newly calculated plan will be exported to Mosaiq to treat the patient.
Device: online CBCT-guided adaptive radiation therapy using a new software
The CBCT will be matched (translated and rotated) to the original planning CT with the clinical image registration software. The rotation simulator reads the image registration of the primary tumor and the match of the lymph node areas. This software also imports the original planning CT and structures and deforms the original planning CT to match the rotations and translations of the primary tumor and lymph node areas, as seen in the CBCT. Both these new radiotherapy planning structures and the deformed planning CT are exported to the radiotherapy planning software (Monaco) and used to calculate the adaptive plan. This newly calculated plan will be exported to Mosaiq to treat the patient.
Device: online CBCT-guided adaptive radiation therapy using a new software
Patients are treated in the NKI with CBCT-guided online adaptive radiotherapy. While in the clinical workflow one planning CT is used to make the radiotherapy plan, this study treatment creates a new radiotherapy plan on the day of every treatment fraction. Instead of directly irradiating, the radiotherapy plan is adjusted to the anatomy of the day.
Feasibility: successful application of the online adaptive treatment in 90% of 20 patients
The adaptive treatment is feasible if the technique is successfully ap-plied in 90% of 20 patients.
Time frame: From first fraction until the last fraction, an average of 20-35 fractions
Safety: Treatment associated ≥ grade 3 acute toxicity according to the NCI Common Terminology Criteria of Adverse Events (CTCAE version 5.0).
Treatment associated ≥ grade 3 acute toxicity according to the NCI Common Terminology Criteria of Adverse Events (CTCAE version 5.0).
Time frame: From Baseline until 3 months after the last radiotherapy fraction
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Oct 2028, 61 months after the start.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 61 months is above that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Netherlands Cancer Institute →